Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 82

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 82
---
 be dissolved and liquidated 51 months following the closing of its initial public offering if it does not complete a business combination in that time, and to remove from the Proposed ParentCo Certificate of Incorporation the various provisions applicable only to special purpose acquisition corporations;

(5)

Advisory Charter Proposal E — to provide that Liminatus will not be subject to Section 203 of the DGCL; and

(6)

Advisory Charter Proposal F — to increase the required vote thresholds for approving amendments to the Proposed ParentCo Certificate of Incorporation and bylaws to 66 2 ∕ 3 %.

A summary of these provisions is set forth in the “ Advisory Charter Proposals (Proposal No. 5)” section of this proxy statement/prospectus. You are encouraged to read them in their entirety.

#### The Election of Directors Proposal
If the Business Combination Proposal and ParentCo Charter Proposal are approved, to consider and vote, on an advisory and non-binding basis, upon a proposal to elect the following three directors to serve on the ParentCo Board: Nicholas Fernandez and Ji Yeon Baek, as Class I directors, until the 2026 annual meeting of stockholders, Eun Sook Lee, as a Class II director, until the 2027 annual meeting of stockholders and Chris Kim as a Class III directors, until the 2028 annual meeting of stockholders, and, in each case, until their respective successors are duly elected and qualified. The election of the directors will be effective at the closing. See the section entitled “ Proposal No. 6 — The Election of Directors Proposal. ”

<div align='center'>16</div>

TABLE OF CONTENTS

#### The Adjournment Proposal
If, based on the tabulated vote, there are not sufficient votes at the time of the Special Meeting to permit us to approve the Business Combination Proposal, the Adjournment Proposal allows us to adjourn the Special Meeting to a later date, if necessary, to permit further solicitation of proxies. See the section entitled “ Proposal No. 7 — The Adjournment Proposal. ”

Quorum and Vote Required for Approval of the Proposals at the Special Meeting

A quorum of our stockholders is necessary to hold a valid meeting. A quorum will be present at the Special Meeting if a majority of the voting power of all outstanding shares of our common stock entitled to vote at the Special Meeting is represented at the meeting in person or by proxy. If a stockholder fails to vote his, her or